Lotte Steuten worked along with Anna Miquel-Cases, Valesca Retèl, and Wim van Harten on a paper on decision about design and priority of studies of emerging predictive biomarkers of high-dose alkylating chemotherapy (HDAC) in triple-negative breast cancer (TNBC). The paper was published in Value in Health.

The information was gathered by a value-of-information analysis. The study shows that further research should be prioritized to the parameter group including “biomarkers’ prevalence, positive predictive value (PPV), and treatment response rates (TRRs).

The full paper can be found here.